RxDoctor Payments Data

Joseph Rudolph, MD

Neurology · Willoughby Hills, OHNPI 1356505341

Payments from drug & device makers

$2,617in general payments, 2019–2025

Across 27 payments — averaging $96.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amneal Pharmaceuticals LLC$2K
  • AbbVie$292
  • Insightec,inc$198
  • Sanofi$129
  • Lundbeck LLC$27
  • CSL Behring$18
  • plus $48 from 4 others

What the payments were for

  • Consulting fees$100%
  • Speaking & faculty fees$1,80069%
  • Food & beverage$80731%

General payments by program year

19
21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,617 in reported general payments places this provider in the 55th percentile of 702 neurology providers in Ohio.

See all neurology providers in Ohio

Medicare billing

Part B allowed, 2024
$81,007
Medicare patients
429
Services billed
898

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate119$667,610
AustedoDeutetrabenazine58$597,092
NourianzIstradefylline101$240,183
IngrezzaValbenazine Tosylate24$196,983
RytaryCarbidopa/Levodopa102$175,006
Nurtec OdtRimegepant Sulfate43$64,877
NeuproRotigotine53$55,790
Rasagiline Mesylate238$48,934
Carbidopa-LevodopaCarbidopa/Levodopa1,194$43,008
Aimovig AutoinjectorErenumab-Aooe26$39,072
NucyntaTapentadol Hcl18$38,759
NuedextaDextromethorphan Hbr/Quinidine25$37,331
Tetrabenazine20$34,614
InbrijaLevodopa12$29,896
MyrbetriqMirabegron36$24,375

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo$12$597,09258 claims
Neurocrine Biosciences, Inc.Ingrezza$15$196,98324 claims
Amneal Pharmaceuticals LLCRytary$1,905$175,006102 claims
PfizerNurtec Odt$16$64,87743 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 702 neurology providers in Ohio.

Other neurology in Willoughby Hills

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →